iLite ADCC Target HER2 Negative Assay Ready Cells


The iLite® Assay Ready Cells are designed for the specific detection of drug potency in serum/plasma as well as neutralizing antibodies in serum/plasma. They utilize an assay technique called reporter gene assay ( RPG ) to analyze serum/plasma samples. The reporter genes utilized are encoded with a bioluminescent luciferase (Firefly luciferase). Different levels of luminescence detected from each reporter gene cell indicates different levels of expression. The Eagle Biosciences iLite® ADCC Target HER2(-) Assay Ready Cells are for research use only.

ADCC Target HER2 Negative Assay Ready Cells

iLite ADCC Target HER2 Negative Assay Ready Cells Developed and Manufactured by Svar Life Science

The iLite ADCC Target HER2 (-) Assay Ready Cells:

  • can be used as negative controls together with iLite ADCC Effector (V) Assay Ready Cells and iLite ADCC Target HER2 (+) Assay Ready Cells for measuring the ADCC activity of anti-HER2 antibodies.

Content: >250 µL of Assay Ready Cells diluted in DMEM with 20% heat inactivated fetal bovine serum (FBS), mixed 1:1 with cryoprotective medium from Lonza (Cat. No 12-132A).

Storage: -80°C, Cells should be used within 30 min of thawing.
For Research Use Only

Key benefits of iLite ADCC Activity Assays

  • Unparalleled sensitivity
  • High serum tolerance
  • Normalization read-out included
  • Negative control available for screening of unspecific activity
  • Easy to use – no culturing required on target or effector cells


Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell.

Breast cancer is the most common cancer in women worldwide, and the second most common cancer overall. Survival rates have improved in the recent years, and stratification of patients into subgroups has vastly improved treatment options for many patients. As an example, patients with HER2 positive breast cancer generally have a poor prognosis, but treatment with trastuzumab, a monoclonal antibody targeting the HER2 receptor, has shown to increase both overall survival and disease free survival when given together with chemotherapy. Trastuzumab’s mechanism of action is mediated in part by inducing ADCC when crosslinking HER2 positive cells with the patient’s immune cells. The drug was FDA approved for treatment of breast cancer patients in 1998, and many biosimilars are currently in development.

Related Products

iLite ADCC Target HER2+ Assay Ready Cells
iLite Effector V Assay Ready Cells

Additional Information


The iLite® ADCC Target HER2 (-) Assay Ready Cells can be used together with iLite® ADCC Effector (V) and iLite® ADCC Target HER2 (+) Assay Ready Cells for the quantification ADCC activity.

Discover the Benefits of iLite


Frequently Asked Questions

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations